{"schema_version":"1.0","type":"article","title":"Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？","url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.md","lang":"zh-Hant","date":"2026-06-02","publish_at":"2026-06-02T10:30:00+08:00","updated_at":"2026-06-02","category":"商業分析系列","topic":"臨床與 CMC","tags":["Biogen","Alzheimer’s Disease","tau","BIIB080","diranersen","ASO","神經退化疾病"],"summary":"Biogen 在 BIIB080 / diranersen 的 Phase 2 CELIA 研究未達主要終點後仍推進 Phase 3，反映 AD 研發裡 tau 靶點的高風險、高需求與策略性押注。","key_points":[],"facts":[],"sections":["01｜CELIA 沒有達主要終點，Biogen 卻說看到了「值得推進」的訊號","02｜Diranersen 的真正吸引力：它不是清除 amyloid，而是從源頭降低 tau","03｜Biogen 為什麼敢推 Phase 3？因為它在 AD 已經沒有太多退路","04｜Biogen 的血淚史：AD 從來不是一個普通疾病市場","05｜AD 賽道不是只有 amyloid，新的競爭版圖正在形成","06｜Diranersen 的最大問題：生物標記能不能變成臨床獲益？","07｜為什麼 Biogen 不能等？因為 CNS 公司的時間成本太高","08｜台灣可以怎麼看？安立璽榮從神經發炎切入阿茲海默症","結語｜Biogen 還不想退出 AD 牌桌，但這一局風險極高"],"references":[],"images":[{"alt":"Biogen 押注 tau 靶點，代表 AD 研發在 amyloid 之外仍尋找能改變疾病進程的新路徑。","url":"https://drugnews.com.tw/assets/articles/biogen-alzheimers-tau-biib080-strategy/dcard-01.webp"},{"alt":"BIIB080 / diranersen 的關鍵不只是單一試驗結果，而是 ASO 能否真正影響 tau 生成與臨床進展。","url":"https://drugnews.com.tw/assets/articles/biogen-alzheimers-tau-biib080-strategy/dcard-02.png"},{"alt":"阿茲海默症研發的高風險，來自龐大需求、複雜病理與臨床終點不確定性的交會。","url":"https://drugnews.com.tw/assets/articles/biogen-alzheimers-tau-biib080-strategy/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biogen-alzheimers-tau-biib080-strategy/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-02）。Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？。https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}